[ad_1] A year ago, data from the Lorelei trial on the taselisib aspirator, Roche's PI3K inhibitor, finally failed and the project was abandoned. Today, at Esmo, Novartis has unveiled the full results …
Read More »[ad_1] By Anette Breindl, Senior Science Writer MUNICH – With more than three years of follow-up, median progression-free survival (PFS) has not yet been reached in the treatment group of the SOLO-1 …
Read More »
[ad_1] MUNICH-Pfizer's Ibrance may have narrowly failed to show it could help relapsed breast cancer patients live longer. But execs contend its recent results still make a "compelling" case. In a phase …
Read More »